Please assess the completion status of the following clinical trial:

Trial Title: Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hoehn \& Yahr stage I\~III~* Patients with idiopathic Parkinson's disease(PD), who meet the United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria, with a good response to levodopa~* The onset of PD symptoms must be occurred \> = 40 years of age (to exclude YOPD), and the patient must have been diagnosed with idiopathic PD \> =40 years of age~* Patients may have symptoms of wearing OFF and/or levodopa induced dyskinesia~* Patients must rate between Hoehn \& Yahr stage I to III, when in an OFF medication state~* Patients must in their optimal medication treatment state, and will not changing their medications within 3 months before and after enrollment~Exclusion Criteria:~* Patients who are proved to be Young Onset Parkinson's Disease (YOPD) and/or genetically related (e.g. Parkin).~* Women of child-bearing potential, pregnant or lactating.~* Patients who are proved to have tumor growth and/or malignancy.~* Patients with a past (within one year) or present history of psychotic symptoms requiring anti- psychotic treatment.~* Patients with active symptoms of major depression with suicidal ideation or suicide attempt.~* Patients with previous brain surgery (including pallidotomy and deep brain stimulation).~* Patients with significant cognitive impairment ( Mini-Mental State Examination, MMSE \< 24).~* Patients who do not sign the inform consent,

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- high dose G-CSF (Type: EXPERIMENTAL): high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
- low dose G-CSF (Type: ACTIVE_COMPARATOR): low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
- placebo (Type: PLACEBO_COMPARATOR): Sodium Chloride (NaCl) 0.9 %

Based on this trial design, predict the completion outcome and termination type (if applicable).